Year Impact Factor (IF) Total Articles Total Cites 2023 (2024 update) 45.5 298 305198 2022 64.5 - 338069 2021 66.850 - 362236 2020 41.582 407 320407 2019 38.637 432 258178 2018 36.216 454 242829 2017 31.398 365 230625 2016 30.410 455 217952 2015 28.710 437 202467 2014 32.242 436 201108 ...
YearImpact Factor (IF)Total ArticlesTotal Cites 2023 (2024 update)7.5-- 20228.8-93064 20219.995-91103 20209.423129673442 20198.109126151089 20187.815125839510 20178.032109029789 20168.282106220705 20157.87080412553 20148.3586716886 20137.2074752416 2012242237 2011-- ...
CD103 mediates T-cell infiltration and organ allograft rejection, and depletion of CD103-expressing cells is a promising therapeutic strategy for allograft intolerance. Recently, we verified that M290-MC-MMAF, an anti-CD103 antibody-drug conjugate, potently eliminates CD103-positive cells in vivo, ...
Furthermore, aberrant vascular endothelial cells (VECs) can also participate in immune inhibition and suppress the function of immune cells in tumor microenvironment by expressing inhibitory receptors such as FasL, VACM-1, PD-L1 (program death ligand 1) and CD73, etc3,4. PD-L1 is one of the...
We defined overall survival in these 54 patients as the date of first surgery to the date of last follow-up or death. RNA extraction and qRT-PCR To test the knockdown efficiency of the lentivirus we constructed against CHSY1 in human colorectal cancer cell lines HCT116, LOVO and mouse ...
Treatment with palmitic acid (PA), an SFA, enhances cell death and suppresses the activity of stimulated T cells. These effects are ameliorated by treatment with oleic acid (OA), a UFA [14]. Additionally, the expression of IL-2 in CD4+ T cells is enhanced by OA, but not by SFA [15...
Consequently, Tex cells impede tumor clearance and contribute to disease perpetuation. The ability to revitalize Tex cells by targeting inhibitory receptors with immune checkpoint blockade (ICB) therapy has greatly improved clinical outcomes in multiple cancer types. Unfortunately, current ICB strategies ...
8 months; hazard ratio for death, 0·34; 95% CI, 0·13 to 0·92; P = 0·034; Fig. 1b). The objective response rate (ORR) was 15·8% in the pembrolizumab group and 0% in the placebo group. The disease control rates (DCR) in the pembrolizumab and placebo groups were ...
Up to that point, the FDA had approved six ICIs targeting programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) for treating locally advanced and metastatic BCa, marking a significant advancement [9]. Nevertheless, the response rate to immunotherapy in BCa patients ...
For the initial quantification of target expression at baseline and after several cycles of immunotherapy (anti-programmed cell death protein 1 (αPD-1)/anti-cytotoxic T-lymphocyte-associated protein 4 (αCTLA-4)) in a MC38 syngeneic colon cancer model via CXCR3-targeted PET, we used a ...